SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS) | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT02131597

SGI-110 in Higher Risk Myelodysplastic Syndrome (MDS)
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The goal of this clinical research study is to learn if SGI-110 can help to control MDS. The safety of this drug will also be studied.

Status: 
Recruiting
Study Date: 
Sat, 11/01/2014 to Fri, 11/01/2019
Intervention: 
Drug: SGI-110 60 mg/m2 subcutaneously daily for 5 days every 4 weeks.